Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab first-line phase II trial in cisplatin-ineligible advanced or metastatic urothelial cancer
2014-002206-20Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in transitional cell carcinoma (TCC), sponsored by Merck & Co. Primary endpoint: Overall response rate. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2014-002206-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002206-20.